AU2001261283B2 - Use of Zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases - Google Patents

Use of Zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases Download PDF

Info

Publication number
AU2001261283B2
AU2001261283B2 AU2001261283A AU2001261283A AU2001261283B2 AU 2001261283 B2 AU2001261283 B2 AU 2001261283B2 AU 2001261283 A AU2001261283 A AU 2001261283A AU 2001261283 A AU2001261283 A AU 2001261283A AU 2001261283 B2 AU2001261283 B2 AU 2001261283B2
Authority
AU
Australia
Prior art keywords
treatment
imidazol
pharmaceutically acceptable
hydroxyethane
diphosphonic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2001261283A
Other languages
English (en)
Other versions
AU2001261283A1 (en
Inventor
Horst Schran
John J. Seaman
Juergen Sigg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9891987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001261283(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2001261283A1 publication Critical patent/AU2001261283A1/en
Application granted granted Critical
Publication of AU2001261283B2 publication Critical patent/AU2001261283B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001261283A 2000-05-19 2001-05-09 Use of Zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases Expired AU2001261283B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0012209.3 2000-05-19
GBGB0012209.3A GB0012209D0 (en) 2000-05-19 2000-05-19 Organic compounds
PCT/US2001/014886 WO2001089494A2 (en) 2000-05-19 2001-05-09 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases

Publications (2)

Publication Number Publication Date
AU2001261283A1 AU2001261283A1 (en) 2002-02-21
AU2001261283B2 true AU2001261283B2 (en) 2005-01-13

Family

ID=9891987

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001261283A Expired AU2001261283B2 (en) 2000-05-19 2001-05-09 Use of Zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
AU6128301A Pending AU6128301A (en) 2000-05-19 2001-05-09 Method of administering a bisphosphonate

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU6128301A Pending AU6128301A (en) 2000-05-19 2001-05-09 Method of administering a bisphosphonate

Country Status (9)

Country Link
EP (1) EP1286665B1 (enExample)
JP (3) JP2004501104A (enExample)
CN (1) CN100389772C (enExample)
AU (2) AU2001261283B2 (enExample)
BR (1) BR0110913A (enExample)
CA (1) CA2409930C (enExample)
ES (1) ES2409033T3 (enExample)
GB (1) GB0012209D0 (enExample)
WO (1) WO2001089494A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014724A1 (en) 2001-05-09 2004-01-22 Seaman John J. Method of administering a bisphosphonate
NZ523086A (en) 2000-06-20 2007-07-27 Novartis Ag Method of administering bisphosphonates
KR20150053811A (ko) 2002-05-10 2015-05-18 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
JP2006500402A (ja) * 2002-09-16 2006-01-05 ノバルティス　アクチエンゲゼルシャフト 股関節骨折後における二次骨折の予防または低減化方法
PL212072B1 (pl) 2002-12-20 2012-08-31 Hoffmann La Roche Tabletka zawierająca jako substancję czynną do 250 mg kwasu ibandronowego oraz sposób jej wytwarzania
MY141763A (en) * 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
BRPI0518874A2 (pt) 2004-12-09 2008-12-16 Merck & Co Inc composto, composiÇço farmacÊutica, e, usos de um composto, e de uma composiÇço
CN101258238B (zh) * 2005-09-08 2014-07-09 迈世耐特股份公司 抗原呈递细胞的活化处理方法
EP2268301B1 (en) * 2008-01-24 2020-02-26 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for bone regeneration
PL2473172T3 (pl) 2009-09-01 2015-08-31 Univ Duke Kompozycje bisfosfonianowe i sposoby do leczenia niewydolności serca
CN102000035B (zh) * 2010-10-13 2012-07-25 江苏奥赛康药业股份有限公司 一种供注射用的唑来膦酸组合物及其制备方法
CN104010647A (zh) 2011-11-16 2014-08-27 杜克大学 用于治疗和/或减轻心功能障碍的双膦酸盐组合物及方法
RU2519120C1 (ru) * 2012-11-06 2014-06-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ профилактики скелетных осложнений у больных с литическими метастазами в плоские и смешанные кости
DE102014004512A1 (de) * 2014-03-28 2015-10-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin Anorganisch-organische Hybridverbindung
BE1021270B1 (nl) * 2014-06-17 2015-10-14 Neogen N.V. Zoledronine oplossing
CN105213407B (zh) * 2015-07-01 2018-01-02 南京大学 唑来膦酸用于制备治疗脂肪性肝病的药物的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014724A1 (en) 2001-05-09 2004-01-22 Seaman John J. Method of administering a bisphosphonate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
ES2409033T3 (es) 2013-06-24
WO2001089494A2 (en) 2001-11-29
GB0012209D0 (en) 2000-07-12
AU6128301A (en) 2001-12-03
CN100389772C (zh) 2008-05-28
BR0110913A (pt) 2003-12-30
EP1286665A2 (en) 2003-03-05
CN1481247A (zh) 2004-03-10
CA2409930A1 (en) 2001-11-29
EP1286665B1 (en) 2013-04-17
JP2012162531A (ja) 2012-08-30
CA2409930C (en) 2012-08-28
WO2001089494A8 (en) 2003-04-17
WO2001089494A3 (en) 2002-05-23
JP2004501104A (ja) 2004-01-15
JP2013151553A (ja) 2013-08-08

Similar Documents

Publication Publication Date Title
JP2012162531A (ja) 骨代謝疾患の処置のための医薬の製造のための、ゾレドロネートの使用
AU2002257802B2 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
AU2002217061B2 (en) Use of bisphosphonates for pain treatment
AU2001261283A1 (en) Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
US5965547A (en) Use of certain methanebishosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
AU2002217061A1 (en) Use of bisphosphonates for pain treatment
AU2002257802A1 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
AU775079B2 (en) Pharmaceutical compositions and uses
US8324189B2 (en) Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
CA2183764C (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
US20040014729A1 (en) Use of estramustine phosphate in the treatment of bone metastasis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired